Oragenics (OGEN) 10-Q2024 Q3 Quarterly report

Filed: 13 Nov 24, 2:40pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: alleging, arrhythmia, awaiting, batch, belief, bone, calendar, cancer, cardiac, cardiotoxicity, Center, chain, channel, charge, Circuit, cold, confident, conspiracy, Continental, contractor, cumbersome, cycle, damage, declared, defraud, Department, disrupt, dissected, division, DNA, Education, electrical, eligible, embroiled, evidence, fall, Food, founded, founder, Frank, function, funneled, genotoxicity, guilty, hERG, IIa, inhibitory, ion, Jacob, Judicial, marrow, MD, micromolar, Mississippi, Nancy, narrow, Needy, nonprofit, Peacock, permitted, plasma, plead, pose, precise, prefilled, prefunded, PresolMD, purity, recover, run, sentencing, shipping, TANF, Trust, unexercised, VanLandingham, vivo, VivoPharm, welfare, wire, wrongdoing

Removed: beginning, Calculation, carryforward, code, cover, deferred, document, embedded, enacted, increasing, Inline, Interactive, IRC, Label, Linkbase, meeting, Pennsylvania, promulgated, realization, restricted, Schema, taxable, Taxonomy, Utilization, utilized, valuation, XBRL

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

OGEN similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

Certification of Principal Executive Officer

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. Section 1350)

In connection with the Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 (the “Report”) of Oragenics, Inc. (the “Registrant”), as filed with the Securities and Exchange Commission on the date hereof, I, J. Michael Redmond, hereby certify, to the best of my knowledge, that:

	(1)	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

	(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.

/s/ J. Michael Redmond
Name: J. Michael Redmond
President and Interim Principal Executive Officer

Date: November 13, 2024

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.